Skip to content

Depression: all studies

Page 794 of 1,034: studies 7,931 to 7,940 of 10,336, newest first. Back to the depression overview

Research

Intranasal esketamine use in bipolar disorder: A case report

Mental Health Clinician July 1, 2021 Courtney Skriptshak, Ashley Reich 11 citations

Abstract Over the past few years, intranasal esketamine has been FDA-approved for treatment-resistant depression as well as MDD with suicidal ideation. In the clinical trials leading to the recent FDA approvals, subjects with a diagnosis of bipolar disorder were excluded from participation in the trial. The manufacturer of intranasal esketamine states that it “has not been studied, and is not...

Fatal intoxication related to two new arylcyclohexylamine derivatives (2F-DCK and 3-MeO-PCE).

Forensic Science International July 1, 2021 Thomas Gicquel, Camille Richeval, Vadim Mesli et al. 45 citations

Continuous development and rapid turnover of drug market of new psychoactive substances (NPS) make it difficult to obtain up-to-date analytical methods for efficient detection of intoxication cases with new substances: no analytical data and no previously published concentration values in biological samples are indeed available. In this context, we aim to report the first fatal case involving...

DOI: 10.1016/j.forsciint.2021.110852 (opens in new tab) Full text (opens in new tab) 2f-dck 3-meo-pce Arylcyclohexylamine derivatives Forensic +3

Subjective experience of aberrant salience in young people at Ultra-High Risk (UHR) for psychosis: a cross-sectional study

Nordic Journal of Psychiatry June 29, 2021 Michele Poletti, L. Pelizza, S. Azzali et al.

Abstract Purpose Aberrant salience (AS) is conceptualized as a potential predisposing factor for psychotic states of mind. Despite several studies in the general population, research on AS in the early phases of psychosis is still relatively scarce. The aim of this cross-sectional study is (1) to evaluate the AS subjective experience in Ultra-High Risk (UHR) adolescents and young adults...

Effects of Mindfulness-Based Cognitive Therapy for Chronic Pain: A Multicenter Study

International Journal of Environmental Research and Public Health June 29, 2021 E. M. Pardos-Gascón, Lucas Narambuena, César Leal-Costa et al.

The prevalence of chronic pain in Spain is 15%. The objective of this study was to evaluate the efficacy of mindfulness-based cognitive therapy on patients with chronic pain. A quasi-experimental design of repeated measures pre- and post-test (N = 57) was carried out at three hospitals from the province of Alicante. Self-reported assessment measurements of pain intensity, anxiety-depression...

Psilocybin for Treating Psychiatric Disorders: Is it a Psychonaut Legend or a Promising Therapeutic Perspective?

Preprints.org June 28, 2021 Maurizio Coppola, Francesco Bevione, Raffaella Mondola 1 citation preprint

Psychedelics extracted by plants have been used in religious, spiritual and mystic practices for millennia. In 1957, Dr. Hofmann have identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although the limitations related to the scientific design of many studies, clinical observations performed during the 1950s and the 1960s...

Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature

Brain Sciences June 27, 2021 Giovanni Martinotti, Stefania Chiappini, Mauro Pettorruso et al. 114 citations

The obsessive-compulsive spectrum refers to disorders drawn from several diagnostic categories that share core features related to obsessive-compulsive disorder (OCD), such as obsessive thoughts, compulsive behaviors and anxiety. Disorders that include these features can be grouped according to the focus of the symptoms, e.g., bodily preoccupation (i.e., eating disorders, ED) or impulse control...

DOI: 10.3390/brainsci11070856 (opens in new tab) Ketamine Eating disorders Obsessive compulsive Substance use +2

Tratak Meditation As a CAM for Stress Management: An EEG Based Analysis

2021 International Conference on Intelligent Technologies June 25, 2021 Swati Kamthekar, Brijesh Iyer

Imbalance of any behavioral pattern and conditions gives rise to stress. Continuous retention of stressed conditions may result in serious health issues such as chronic disease, mental disorder, depression, anxiety, and worse quality of life. As conventional medication causes severe side effects, complementary and alternative medicines are in the highest demand for stress reduction. The paper...

Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders

Canadian Journal of Health Technologies June 24, 2021 Yi‐sheng Chao, Jennifer Horton 5 citations

Two systematic reviews, 3 randomized controlled trials, and 2 single-arm safety trials were identified that evaluated several combinations of psychedelic-assisted psychotherapy. Psilocybin was the psychedelic most tested. Other psychedelics identified in the systematic reviews and primary studies were 3,4-methylenedioxymethamphetamine (or MDMA), lysergic acid diethylamide (or LSD), ayahuasca...

Meditation and Mindfulness in Pregnancy and Postpartum: A Review of the Evidence.

Clinical obstetrics and gynecology June 23, 2021 S. Babbar, Alejandro J Oyarzabal, E. Oyarzabal

Given their growing popularity, mindfulness practices including meditation are actively being studied in clinical trials to assess their efficacy at improving health outcomes during pregnancy and the postpartum period. We conducted a literature review to compile these studies and assessed their findings. There is sufficient evidence to support the practice of mindfulness practices in pregnancy...

Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse

Expert Opinion on Drug Metabolism & Toxicology June 18, 2021 M. Luz, Deborah C. Mash 30 citations

Ibogaine is a psychoactive indole alkaloid isolated from the West African shrub Tabernanthe iboga. It has been used by indigenous cultures to combat fatigue, hunger, and thirst, and to induce hallucinations during religious ceremonies. First isolated in 1901, ibogaine was initially recommended for use in asthenia at doses of 10 to 30 mg per day [1,2]. Semi-synthetic ibogaine came into use in...